- Home
- CSIQ vs GERN Comparison
CSIQ vs GERN Comparison
Compare CSIQ & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSIQ
- GERN
- Stock Information
- Founded
- CSIQ 2001
- GERN 1990
- Country
- CSIQ Canada
- GERN United States
- Employees
- CSIQ N/A
- GERN N/A
- Industry
- CSIQ Semiconductors
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- CSIQ Technology
- GERN Health Care
- Exchange
- CSIQ Nasdaq
- GERN Nasdaq
- Market Cap
- CSIQ 715.3M
- GERN 853.5M
- IPO Year
- CSIQ 2006
- GERN 1996
- Fundamental
- Price
- CSIQ $11.24
- GERN $1.60
- Analyst Decision
- CSIQ Hold
- GERN Buy
- Analyst Count
- CSIQ 11
- GERN 9
- Target Price
- CSIQ $16.49
- GERN $5.13
- AVG Volume (30 Days)
- CSIQ 1.4M
- GERN 12.2M
- Earning Date
- CSIQ 05-15-2025
- GERN 05-07-2025
- Dividend Yield
- CSIQ N/A
- GERN N/A
- EPS Growth
- CSIQ N/A
- GERN N/A
- EPS
- CSIQ N/A
- GERN N/A
- Revenue
- CSIQ $5,860,923,000.00
- GERN $116,293,000.00
- Revenue This Year
- CSIQ $24.47
- GERN $160.12
- Revenue Next Year
- CSIQ $17.17
- GERN $55.01
- P/E Ratio
- CSIQ N/A
- GERN N/A
- Revenue Growth
- CSIQ N/A
- GERN 22264.04
- 52 Week Low
- CSIQ $6.57
- GERN $1.17
- 52 Week High
- CSIQ $19.55
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- CSIQ 62.22
- GERN 60.78
- Support Level
- CSIQ $9.53
- GERN $1.50
- Resistance Level
- CSIQ $10.65
- GERN $1.60
- Average True Range (ATR)
- CSIQ 0.60
- GERN 0.12
- MACD
- CSIQ 0.05
- GERN 0.03
- Stochastic Oscillator
- CSIQ 86.36
- GERN 92.13
About CSIQ Canadian Solar Inc. (ON)
Canadian Solar Inc is a Canadian solar technology and renewable energy company. It is a manufacturer of solar photovoltaic modules, a provider of battery energy storage solutions, and a developer of utility-scale solar power and battery energy storage projects.. It operates through two business segments CSI Solar and Recurrent Energy segment. The CSI Solar segment focused on solar modules and battery energy storage manufacturing and products. Its Recurrent segment focused on utility-scale solar power and battery energy storage project development and operation. Key revenue is generated from CSI Solar segment.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.